Trial reportPloS one2013
Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01445223 (A Study on ART Naïve Patients On Different Regimens to Treat Hiv), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study on ART Naïve Patients On Different Regimens to Treat Hiv (a Phase 4 Study)
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.Science translational medicine · 2019Trial
- Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.HIV medicine · 2014Trial
- Flagellin Restricts HIV-1 Infection of Macrophages through Modulation of Viral Entry Receptors and CC Chemokines.Viruses · 2024Article
- Cardiovascular Disease and Thrombosis in HIV Infection.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV.Frontiers in immunology · 2023Review
- Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus.The Journal of infectious diseases · 2021Article
- Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy.The Journal of infectious diseases · 2020Article
- Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Reduced Transplacental Transfer of Antimalarial Antibodies in Kenyan HIV-Exposed Uninfected Infants.Open forum infectious diseases · 2019Article
- Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.PloS one · 2019Article
- Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers.Scientific reports · 2017Article
- Very Early ART and Persistent Inflammation in Treated HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Inflammation, immune activation, and cardiovascular disease in HIV.AIDS (London, England) · 2016 · on this mapReview
- Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals.AIDS (London, England) · 2016Article
- Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy.Clinical pharmacology and therapeutics · 2016Review
- Brief Report: Differential Associations of Interleukin 6 and Intestinal Fatty Acid-Binding Protein With Progressive Untreated HIV-1 Infection in Rakai, Uganda.Journal of acquired immune deficiency syndromes (1999) · 2016Article
- Article
- Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting.Journal of acquired immune deficiency syndromes (1999) · 2014Article
- Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection.AIDS (London, England) · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe investigated whether there are differences in the effects on microbial translocation (MT) and enterocyte damage by different antiretroviral therapy (ART) regimens after 1.5 years and whether antibiotic use has impact on MT. In a randomized clinical trial (NCT01445223) on first line ART, patients started either lopinavir/r (LPV/r) (n = 34) or efavirenz (EFV) containing ART (n = 37). Lipopolysaccharide (LPS), sCD14, anti-flagellin antibodies and intestinal fatty acid binding protein (I-FABP) levels were determined in plasma at baseline (BL) and week 72 (w72).
resultsThe levels of LPS and sCD14 were reduced from BL to w72 (157.5 pg/ml vs. 140.0 pg/ml, p = 0.0003; 3.13 ug/ml vs. 2.85 ug/ml, p = 0.005, respectively). The levels of anti-flagellin antibodies had decreased at w72 (0.35 vs 0.31 [OD]; p<0.0004), although significantly only in the LPV/r arm. I-FABP levels increased at w72 (2.26 ng/ml vs 3.13 ng/ml; p<0.0001), although significantly in EFV treated patients only. Patients given antibiotics at BL had lower sCD14 levels at w72 as revealed by ANCOVA compared to those who did not receive (Δ = -0.47 µg/ml; p = 0.015).
conclusionsMarkers of MT and enterocyte damage are elevated in untreated HIV-1 infected patients. Long-term ART reduces the levels, except for I-FABP which role as a marker of MT is questionable in ART-experienced patients. Why the enterocyte damage seems to persist remains to be established. Also antibiotic usage may influence the kinetics of the markers of MT.
trial registrationClinicalTrials.gov NCT01445223.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.